Halozyme Therapeutics Inc HALO

Healthcare Biotechnology

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

NDAQ:HALO - Post by User

Halozyme Therapeutics Inc

<< Previous

Bullboard Posts

Post by whytestockson Jun 06, 2024 4:00pm

53 Views

Post# 36076131

Halozyme's ENHANZE Product Gets New Patent Grant in EU | Ben

Just In: $HALO Halozyme's ENHANZE Product Gets New Patent Grant in EU | BenzingaHalozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...HALO - Halozyme's ENHANZE Product Gets New Patent Grant in EU | Benzinga

<< Previous

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?